Statement: The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall.
Primary_evidence: INTERVENTION 1:    Lapatinib Plus Paclitaxel   Participants received lapatinib 1500 mg orally OD with paclitaxel, administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.
Secondary_evidence: INTERVENTION 1:    Urea/Lactic Acid Cream   Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily. INTERVENTION 2:    Placebo Cream   Patients receive placebo cream applied to palms and soles twice daily.